Literature DB >> 29450978

Prognostic comparison of the 7th and 8th editions of the American Joint Committee on Cancer staging system for intrahepatic cholangiocarcinoma.

Sang-Hyun Kang1, Shin Hwang1, Young-Joo Lee1, Ki-Hun Kim1, Chul-Soo Ahn1, Deok-Bog Moon1, Tae-Yong Ha1, Gi-Won Song1, Dong-Hwan Jung1, Sung-Gyu Lee1.   

Abstract

BACKGROUND: Several important changes were made to the 8th edition of the American Joint Committee on Cancer (AJCC) tumor staging system for intrahepatic cholangiocarcinoma (ICC). We assessed the prognostic impact of this new tumor staging system compared to the 7th edition.
METHODS: A retrospective single-institution study was performed with 626 patients who underwent R0 resection for ICC over 20-year period.
RESULTS: Anatomical resection and concurrent bile duct resection were performed in 571 (91.2%) and 62 (9.9%) patients, respectively. Cumulative tumor recurrence and patient survival rates were 40.6% and 73.3% at 1 year; 66.7% and 43.8% at 3 years; 73.6% and 30.4% at 5 years; and 74.4% and 20.3% at 10 years, respectively. Independent prognostic factors for tumor recurrence and patient survival were multiple tumors, carbohydrate antigen 19-9 >200 U/ml, tumor size >5 cm, direct invasion to extrahepatic structure, and lymph node metastasis. For tumor-node-metastasis stages in the 7th versus the 8th editions, concordance index was 0.615 and 0.625 for tumor recurrence and 0.626 and 0.628 for patient survival, respectively.
CONCLUSIONS: The 8th edition of the AJCC staging system appears to provide high prognostic contrast for T stage categories, except for T3. However, overall prognostic performance of the 8th edition was not markedly improved over the 7th edition.
© 2018 Japanese Society of Hepato-Biliary-Pancreatic Surgery.

Entities:  

Keywords:  Intrahepatic cholangiocarcinoma; Prognosis; Recurrence; Resection

Mesh:

Year:  2018        PMID: 29450978     DOI: 10.1002/jhbp.543

Source DB:  PubMed          Journal:  J Hepatobiliary Pancreat Sci        ISSN: 1868-6974            Impact factor:   7.027


  13 in total

Review 1.  Cholangiocarcinoma 2020: the next horizon in mechanisms and management.

Authors:  Jesus M Banales; Jose J G Marin; Angela Lamarca; Pedro M Rodrigues; Shahid A Khan; Lewis R Roberts; Vincenzo Cardinale; Guido Carpino; Jesper B Andersen; Chiara Braconi; Diego F Calvisi; Maria J Perugorria; Luca Fabris; Luke Boulter; Rocio I R Macias; Eugenio Gaudio; Domenico Alvaro; Sergio A Gradilone; Mario Strazzabosco; Marco Marzioni; Cédric Coulouarn; Laura Fouassier; Chiara Raggi; Pietro Invernizzi; Joachim C Mertens; Anja Moncsek; Sumera Rizvi; Julie Heimbach; Bas Groot Koerkamp; Jordi Bruix; Alejandro Forner; John Bridgewater; Juan W Valle; Gregory J Gores
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2020-06-30       Impact factor: 46.802

2.  Comparison of Hepatic Arterial Infusion Pump Chemotherapy vs Resection for Patients With Multifocal Intrahepatic Cholangiocarcinoma.

Authors:  Stijn Franssen; Kevin C Soares; Joshua Samuel Jolissaint; Diamantis I Tsilimigras; Stefan Buettner; Sorin Alexandrescu; Hugo Marques; Jorge Lamelas; Luca Aldrighetti; T Clark Gamblin; Shishir K Maithel; Carlo Pulitano; Georgios A Margonis; Matthew J Weiss; Todd W Bauer; Feng Shen; George A Poultsides; James Wallis Marsh; Andrea Cercek; Nancy Kemeny; T Peter Kingham; Michael D'Angelica; Timothy M Pawlik; William R Jarnagin; Bas Groot Koerkamp
Journal:  JAMA Surg       Date:  2022-07-01       Impact factor: 16.681

3.  Reappraisal of the T Category for Solitary Intrahepatic Cholangiocarcinoma by Tumor Size in 611 Early-Stage (T1-2N0M0) Patients After Hepatectomy: a Surveillance, Epidemiology, and End Results (SEER) Analysis.

Authors:  YiPing Chen; ShanGeng Weng
Journal:  J Gastrointest Surg       Date:  2020-11-02       Impact factor: 3.452

4.  Surgical management of biliary malignancy.

Authors:  T Peter Kingham; Victoria G Aveson; Alice C Wei; Jason A Castellanos; Peter J Allen; Daniel P Nussbaum; Yinin Hu; Michael I D'Angelica
Journal:  Curr Probl Surg       Date:  2020-06-30       Impact factor: 1.909

5.  A Novel Prognostic Nomogram for Patients With Recurrence of Intrahepatic Cholangiocarcinoma After Initial Surgery.

Authors:  Kai-Li Xing; Liang-He Lu; Xin Huang; Chao-Bin He; Yun-Da Song; Rong-Ping Guo; Sheng-Ping Li
Journal:  Front Oncol       Date:  2020-04-02       Impact factor: 6.244

6.  Evaluation of Preoperative Inflammation-Based Prognostic Scores in Patients With Intrahepatic Cholangiocarcinoma: A Multicenter Cohort Study.

Authors:  Chaobin He; Chongyu Zhao; Jiawei Lu; Xin Huang; Cheng Chen; Xiaojun Lin
Journal:  Front Oncol       Date:  2021-06-17       Impact factor: 6.244

7.  Liver Metastases of Intrahepatic Cholangiocarcinoma: Implications for an Updated Staging System.

Authors:  Angela Lamarca; Alvaro Santos-Laso; Kirsten Utpatel; Adelaida La Casta; Simone Stock; Alejandro Forner; Jorge Adeva; Trine Folseraas; Luca Fabris; Rocio I R Macias; Marcin Krawczyk; Marek Krawczyk; Vincenzo Cardinale; Chiara Braconi; Domenico Alvaro; Matthias Evert; Jesus M Banales; Juan W Valle
Journal:  Hepatology       Date:  2021-06       Impact factor: 17.425

8.  Impact of surgical margin width on long-term outcomes for intrahepatic cholangiocarcinoma: a multicenter study.

Authors:  Hongzhi Liu; Lianku Lin; Ziguo Lin; Yifan Chen; Qizhen Huang; Lei Ding; Jianying Lou; Shuguo Zheng; Xinyu Bi; Jianming Wang; Wei Guo; Fuyu Li; Jian Wang; Yamin Zheng; Jingdong Li; Shi Cheng; Weiping Zhou; Zhangjun Cheng; Yongyi Zeng
Journal:  BMC Cancer       Date:  2021-07-20       Impact factor: 4.430

9.  Fibrinogen/albumin ratio index is an independent predictor of recurrence-free survival in patients with intrahepatic cholangiocarcinoma following surgical resection.

Authors:  Hu Liu; Guoteng Qiu; Fengjuan Hu; Hong Wu
Journal:  World J Surg Oncol       Date:  2021-07-20       Impact factor: 2.754

10.  Perineural invasion as a prognostic factor for intrahepatic cholangiocarcinoma after curative resection and a potential indication for postoperative chemotherapy: a retrospective cohort study.

Authors:  Zeyu Zhang; Yufan Zhou; Kuan Hu; Dong Wang; Zhiming Wang; Yun Huang
Journal:  BMC Cancer       Date:  2020-03-30       Impact factor: 4.430

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.